MedTrace Logo

Different Regimens of Transarterial Chemoembolization for Hepatocellular Carcinoma

NCT00493402 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 365

Last updated 2012-12-17

No results posted yet for this study

Summary

The purpose of this study is to evaluate efficacy, safety, and patient reported outcomes (PRO) of different regimens of transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC).

Conditions

Interventions

PROCEDURE

Transarterial chemoembolization (TACE)

drugs and dosage: chemotherapy with lipiodol mixed with EADM 50mg, lobaplatin 50mg, and MMC 6mg, plus particle embolization.

PROCEDURE

Transarterial chemoembolization (TACE)

drugs and dosage: chemotherapy with lipiodol mixed with EADM 50mg, lobaplatin 50mg, and MMC 6mg.

PROCEDURE

Transarterial chemoembolization (TACE)

Drugs and dosage:chemotherapy with lipiodol mixed with EADM 50mg, plus particle embolization.

Sponsors & Collaborators

  • Ministry of Health, China

    collaborator OTHER_GOV

  • Guangdong Provincial People's Hospital

    collaborator OTHER

  • The 458 Hospital of Chinese PLA

    collaborator OTHER

  • Kaiping Central Hospital

    collaborator OTHER

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Jin-Qing Li, M.D. · Cancer Center, Sun Yat-set University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2010-12-31
Completion
2010-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00493402 on ClinicalTrials.gov